secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033066
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026
----------------------------------------------------------------------------

- Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).
- Cash, cash equivalents, and investments: $367.4M as of Dec 31, 2022; cash runway into 2026.
- Collaboration revenue from BMS: $5.2M for FY2022.
- Phase 1 ELiPSE-1 trial of CNTY-101 dosed first patient in Feb 2023; initial data by year-end 2023.
- FY2023 GAAP operating expense guidance: $135M-$145M, incl. $12M-$17M stock-based comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/0001104659-23-033066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/tm239540d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer